List of Rezzayo drug patents
Rezzayo is owned by Cidara Theraps.
Rezzayo contains Rezafungin Acetate.
Rezzayo has a total of 4 drug patents out of which 0 drug patents have expired.
Rezzayo was authorised for market use on 22 March, 2023.
Rezzayo is available in powder;intravenous dosage forms.
Rezzayo can be used as treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration.
Drug patent challenges can be filed against Rezzayo from 2032-03-22.
The generics of Rezzayo are possible to be released after 14 July, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8722619 | CIDARA THERAPS | Antifungal agents and uses thereof |
Mar, 2032
(8 years from now) | |
| US10702573 | CIDARA THERAPS | Dosing regimens for echinocandin class compounds |
Mar, 2033
(9 years from now) | |
| US9526835 | CIDARA THERAPS | Dosing regimens for echinocandin class compounds |
Mar, 2033
(9 years from now) | |
| US11197909 | CIDARA THERAPS | Compositions and methods for the treatment of fungal infections |
Jul, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Mar 22, 2030 |
| New Chemical Entity Exclusivity (NCE) | Mar 22, 2028 |
| Generating Antibiotic Incentives Now (GAIN) | Mar 22, 2033 |
Drugs and Companies using REZAFUNGIN ACETATE ingredient
NCE-1 date: 2032-03-22
Market Authorisation Date: 22 March, 2023
Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration
Dosage: POWDER;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic